Combined BRAF and MEK inhibition in BRAF-mutant NSCLC
Mené sur 59 patients atteints d'un cancer métastatique du poumon non à petites cellules présentant la mutation V600E du gène BRAF, cet essai international non randomisé de phase II évalue l'efficacité, du point de vue de la réponse globale, et la toxicité d'un traitement combinant dabrafénib et tramétinib
In the past two decades many of the molecular drivers of non-small-cell lung cancer (NSCLC) have been elucidated and therapies targeting these changes have offered new hope and improved survival for patients. In NSCLC, these treatments have been honed in the treatment of EGFR-mutated and ALK-mutated disease, but despite the success of BRAF-directed treatment in cutaneous melanoma, only small numbers of patients with NSCLC have received BRAF-directed therapy in prospective studies.
The Lancet Oncology , commentaire, 2015